For decades, CMC's safety profile rested on traditional toxicology: animal studies showing no organ damage, no carcinogenicity, no acute toxicity at high doses. Regulators concluded it was safe, set an ADI (Acceptable Daily Intake), and moved on.
What those traditional tests did not examine was the gut microbiome. They were designed to detect toxicity, not to study whether a substance altered the composition and function of the bacterial ecosystem living in the human gut. That question was not the primary lens of food safety science in the 1980s or 1990s.
It became the primary lens by the 2010s.
Animal Studies: A Consistent Pattern
The research that began changing the CMC conversation was published in 2015 in Nature. A team led by Benoit Chassaing found that mice fed CMC or polysorbate 80 (another common emulsifier) developed low-grade intestinal inflammation and metabolic syndrome. The microbiota of CMC-treated mice showed reduced diversity, with increases in pro-inflammatory bacteria and decreases in beneficial species. The inner mucus layer of the gut, which normally keeps bacteria from contacting the intestinal epithelium, became thinner. Bacteria encroached closer to the gut wall than in control animals.
Subsequent animal studies replicated and extended those findings. A 2020 paper in Cell Reports31218-3) found that CMC and polysorbate 80 directly induced expression of virulence genes in adherent-invasive E. coli (AIEC), a pathobiont associated with Crohn's disease. The emulsifiers appeared to make this bacterium more motile and better able to colonize the intestinal epithelium, providing a mechanism by which they could drive chronic inflammation in genetically susceptible individuals.
A 2024 paper in Communications Biology found that CMC and polysorbate 80 promoted metabolic disorders and intestinal microbiota dysbiosis in mice, with CMC showing particularly consistent effects on microbiota composition and gut barrier function. CMC also raised circulating LPS (lipopolysaccharide) levels, a marker of bacterial product translocation across the gut barrier into the bloodstream. Elevated LPS drives systemic low-grade inflammation, which has been linked to metabolic syndrome, type 2 diabetes, and cardiovascular risk.
Across these studies, the direction of findings is consistent: CMC disrupts the gut microbiome, thins the protective mucus layer, and increases gut permeability in mouse models.
The Human Study
Animal models are informative but not definitive. The more important question is what CMC does in the human gut. One clinical trial has now addressed this directly.
A randomized controlled trial of healthy participants, reported in Gastroenterology, examined the effects of consuming 15 grams of CMC per day for approximately two weeks. The results tracked closely with what the animal studies had found. CMC consumers showed:
- Increased postprandial abdominal discomfort
- Lowered gut microbiome diversity
- Decreased fecal concentrations of short-chain fatty acids, including butyrate (a key fuel for colonocytes and a driver of gut barrier health)
- Decreased levels of beneficial bacteria including Faecalibacterium prausnitzii and Akkermansia muciniphila
- Enhanced encroachment of microbiota into the inner mucus layer
The Important Caveat
15 grams per day is a high CMC intake. Most people consuming food with CMC as an ingredient take in far less. A generous serving of ice cream might contain 0.3 to 0.5 grams. Even a day of eating multiple CMC-containing foods would be unlikely to reach 15 grams.
This caveat is significant. The clinical trial established that CMC can alter the human gut microbiome at a dose high enough to detect, but it does not tell us whether the smaller, cumulative doses typical of everyday eating produce similar effects. Researchers have called for long-term studies at realistic dietary doses. Those studies have not yet been published.
What the trial does establish is a human proof-of-concept. The animal findings were not an artifact of mouse physiology. CMC acts on the human gut microbiome in measurable ways.